Alzheimer’s disease: the FDA approves a new anti-amyloid antibody
Washington, United States — Lecanemab (Lequembi®, Eisai), an anti-amyloid beta protofibril antibody, has been approved by the Food and Drug Administration (FDA) in the treatment of Alzheimer’s disease. This is the second antibody targeting amyloid β plaques to receive marketing authorization in this indication. Like the controversial aducanumab (Aduhelm®, Biogen/Eisai), lecanemab was approved under an …
Alzheimer’s disease: the FDA approves a new anti-amyloid antibody Read More »